Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)

Grzegorz S. Nowakowski; Dok Hyun Yoon; Patrizia Mondello; Erel Joffe; Anthea Peters; Isabelle Fleury; Richard Greil; Matthew Ku; Reinhard Marks; Kibum Kim; Pier Luigi Zinzani; Judith Trotman; Lorenzo Sabatelli; Eva E. Waltl; Mark Winderlich; Andrea Sporchia; Nuwan C. Kurukulasuriya; Raul Cordoba; Georg Hess; Gilles Salles

doi:10.1007/s00277-023-05321-3

Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)

Grzegorz S. Nowakowski^*, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper. The original article has been corrected.

Original language	English
Pages (from-to)	2643-2644
Number of pages	2
Journal	Annals of Hematology
Volume	102
Issue number	9
DOIs	https://doi.org/10.1007/s00277-023-05321-3
State	Published - Sep 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00277-023-05321-3

Fingerprint

Dive into the research topics of 'Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)'. Together they form a unique fingerprint.

Cite this

Nowakowski, G. S., Yoon, D. H., Mondello, P., Joffe, E., Peters, A., Fleury, I., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, P. L., Trotman, J., Sabatelli, L., Waltl, E. E., Winderlich, M., Sporchia, A., Kurukulasuriya, N. C., Cordoba, R., Hess, G., & Salles, G. (2023). Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4). Annals of Hematology, 102(9), 2643-2644. https://doi.org/10.1007/s00277-023-05321-3

Nowakowski, Grzegorz S. ; Yoon, Dok Hyun ; Mondello, Patrizia et al. / Correction to : RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4). In: Annals of Hematology. 2023 ; Vol. 102, No. 9. pp. 2643-2644.

@article{84541e488aca47e387ea1e49f03de9fe,

title = "Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)",

abstract = "Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper. The original article has been corrected.",

author = "Nowakowski, {Grzegorz S.} and Yoon, {Dok Hyun} and Patrizia Mondello and Erel Joffe and Anthea Peters and Isabelle Fleury and Richard Greil and Matthew Ku and Reinhard Marks and Kibum Kim and Zinzani, {Pier Luigi} and Judith Trotman and Lorenzo Sabatelli and Waltl, {Eva E.} and Mark Winderlich and Andrea Sporchia and Kurukulasuriya, {Nuwan C.} and Raul Cordoba and Georg Hess and Gilles Salles",

note = "Publisher Copyright: {\textcopyright} 2023, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2023",

month = sep,

doi = "10.1007/s00277-023-05321-3",

language = "אנגלית",

volume = "102",

pages = "2643--2644",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

Nowakowski, GS, Yoon, DH, Mondello, P, Joffe, E, Peters, A, Fleury, I, Greil, R, Ku, M, Marks, R, Kim, K, Zinzani, PL, Trotman, J, Sabatelli, L, Waltl, EE, Winderlich, M, Sporchia, A, Kurukulasuriya, NC, Cordoba, R, Hess, G & Salles, G 2023, 'Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)', Annals of Hematology, vol. 102, no. 9, pp. 2643-2644. https://doi.org/10.1007/s00277-023-05321-3

Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4). / Nowakowski, Grzegorz S.; Yoon, Dok Hyun; Mondello, Patrizia et al.
In: Annals of Hematology, Vol. 102, No. 9, 09.2023, p. 2643-2644.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)

AU - Nowakowski, Grzegorz S.

AU - Yoon, Dok Hyun

AU - Mondello, Patrizia

AU - Joffe, Erel

AU - Peters, Anthea

AU - Fleury, Isabelle

AU - Greil, Richard

AU - Ku, Matthew

AU - Marks, Reinhard

AU - Kim, Kibum

AU - Zinzani, Pier Luigi

AU - Trotman, Judith

AU - Sabatelli, Lorenzo

AU - Waltl, Eva E.

AU - Winderlich, Mark

AU - Sporchia, Andrea

AU - Kurukulasuriya, Nuwan C.

AU - Cordoba, Raul

AU - Hess, Georg

AU - Salles, Gilles

PY - 2023/9

Y1 - 2023/9

N2 - Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper. The original article has been corrected.

AB - Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85164467547&partnerID=8YFLogxK

U2 - 10.1007/s00277-023-05321-3

DO - 10.1007/s00277-023-05321-3

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 37432417

AN - SCOPUS:85164467547

SN - 0939-5555

VL - 102

SP - 2643

EP - 2644

JO - Annals of Hematology

JF - Annals of Hematology

IS - 9

ER -

Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I et al. Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4). Annals of Hematology. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this